20 May 2003 : Original article
Living related donor liver transplantation from Hepatitis B core antibody positive donor
I. Jankowska, J. Pawłowska, P. Kaliciński, M. Teisseyre, A. Kamiński, J. Kuszyk, P. Kluge, M. Pronicki, J. SochaMed Sci Monit 2003; 9(2): 20-0 :: ID: 15303
Abstract
Background: Transmissions of hepatitis B virus (HBV)infection from donors negative for hepatitis B surface antigen (HBsAg)but positive for antibody to hepatitis B core antigen (anti-HBc) have been reported.The recipient risk to develop hepatitis B from an anti-HBc positive donors has been estimated to be up to 78%but in emergency cases the decision to perform trans- plantation should be considered. The aim of the study was to analyse the outcome of living related anti-HBc positive donor liver transplantation in children. Material/Methods:3 out of 88 children with living related liver transplantation received a liver from an anti-HBc positive donor.All children had liver cirrhosis due to biliary atresia. Transplantation was done at the age of 12.21 and 22 months, in life-threatening situations,after 6 month waiting time for cadaveric liver transplantation.Recipients were HBsAg and anti-HBc negative.All children were vaccinated before transplantation with anti-HBs title above 1000 mIU/ml on the day of transplantation.In all living related donors HBsAg and anti-HBc antibody were determined before transplantation. Three anti-HBc positive donors were tested for HBV DNA in serum and liver by PCR method. Results:Serum of all anti-HBc positive donors was negative for HBV DNA. Liver biopsies showed no inflammation but in two cases liver tissue was positive for HBV-DNA by PCR test.All three recipients are followed up for 10 –24 months after liver transplantation.None of them developed HBV infection. Conclusions: 1.In case of life threatening situations anti-HBc positive donors can be accepted for living related liver transplantation.2.It is important to vaccinate and verify the antibody response to the vaccination before and after transplantation.
Keywords: Hepatitis B
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952